Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Net Cash per Share : $4.24 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Amylyx Pharmaceuticals Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Amylyx Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2023 was $4.24.

The historical rank and industry rank for Amylyx Pharmaceuticals's Net Cash per Share or its related term are showing as below:

AMLX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.41 Med: 5.89 Max: 8.3
Current: 0.45

During the past 5 years, the highest Price-to-Net-Cash Ratio of Amylyx Pharmaceuticals was 8.30. The lowest was 0.41. And the median was 5.89.

AMLX's Price-to-Net-Cash is ranked better than
96.54% of 867 companies
in the Biotechnology industry
Industry Median: 4.01 vs AMLX: 0.45

Amylyx Pharmaceuticals Net Cash per Share Historical Data

The historical data trend for Amylyx Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amylyx Pharmaceuticals Net Cash per Share Chart

Amylyx Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

-0.56

-1.48

-2.91

4.45

4.24

Amylyx Pharmaceuticals Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Cash per Share	Get a 7-Day Free Trial										4.45	4.33	4.31	4.55	4.24

Competitive Comparison of Amylyx Pharmaceuticals's Net Cash per Share

For the Biotechnology subindustry, Amylyx Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amylyx Pharmaceuticals's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amylyx Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's Price-to-Net-Cash falls into.

Amylyx Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Amylyx Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(371.362	-	84.022	-	0)	/	67.7074
=	4.24

Amylyx Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(371.362	-	84.022	-	0)	/	67.7074
=	4.24

Amylyx Pharmaceuticals (NAS:AMLX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Amylyx Pharmaceuticals Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amylyx Pharmaceuticals Inc (NAS:AMLX) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

43 Thorndike Street, Cambridge, MA, USA, 02141

Website

https://www.amylyx.com

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Executives

Joshua B Cohen	director, officer: Co-Chief Executive Officer	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Justin B. Klee	director, officer: Co-Chief Executive Officer	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Patrick D Yeramian	officer: Chief Medical Officer	1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486
James M Frates	officer: Chief Financial Officer	88 SIDNEY ST, CAMBRIDGE MA 021394136
Karen Firestone	director	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141
Gina Mazzariello	officer: Chief Legal Officer	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Morningside Venture Investments Ltd	10 percent owner	MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Milne George M Jr	director
Margaret Olinger	officer: Chief Commercial Officer	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 96 Llc	10 percent owner	55 RAILROAD AVE., GREENWICH CT 06830
Als Invest 1 B.v.	10 percent owner	EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017
Isaac Cheng	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Mvil, Llc	10 percent owner	22ND FLOOR HANG LUNG CENTRE, 2-20 PATERSON STREET, CAUSEWAY BAY K3 00000
Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901